EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAPP)

被引：0

作者：

Cardona, A. ^{[1
]}

Ruiz-Patino, A. ^{[1
]}

Castro, C. ^{[1
]}

Rojas, L. ^{[2
]}

Arrieta, O. ^{[3
,4
]}

Zatarain-Barron, Z. ^{[5
,6
]}

Carranza, H. ^{[1
]}

Vargas, C. ^{[1
]}

Otero, J. ^{[1
]}

Corrales, L. ^{[7
]}

Martin, C. ^{[8
]}

Rosell, R. ^{[9
]}

机构：

[1] Fdn Clin & Appl Canc Res Ficmac, Clin & Translat Oncol Grp, Bogota, Colombia

[2] Clin Univ Colombia, Med Oncol, Bogota, Colombia

[3] Natl Canc Inst, Unidad Func Oncol Torac, Mexico City, DF, Mexico

[4] Natl Canc Inst, Lab Med Personalizada, Mexico City, DF, Mexico

[5] Inst Nacl Cancerol, Thorac Oncol Unit, Mexico City, DF, Mexico

[6] Inst Nacl Cancerol, Lab Personalized Med, Mexico City, DF, Mexico

[7] Hosp San Jose, Clin Oncol, San Jose, Costa Rica

[8] Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina

[9] Germans Trias & Pujol Hlth Sci Inst & Hosp, Canc Biol & Precis Med Program, Catalan Inst Oncol, Barcelona, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

EGFR mutations; EGFR amplification; Adenocarcinoma;

D O I：

10.1016/j.jtho.2018.08.1406

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.13-11

引用

页码：S802 / S802

页数：1

共 50 条

[21] Detecting EGFR Mutations from Plasma cfDNA in Lung Adenocarcinoma Patients
Hung, M.
Lung, J.
Lin, Y.
Fang, Y.
Tsai, Y.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[22] Survival of lung adenocarcinoma patients with uncommon EGFR mutations in routine clinical practice in Slovenia
Stanic, K.
Hitij, N. Turnsek
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S131 - S132
[23] EFFICACY OF GEFITINIB AND ERLOTINIB IN INDONESIAN PATIENTS WITH LUNG ADENOCARCINOMA WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
Asdar, Muhammad Ali
Syahruddin, Elisna
Zaini, Jamal
RESPIROLOGY, 2019, 24 : 55 - 56
[24] EGFR kinase domain mutations, but not copy number, predict response to erlotinib and gefitinib in patients with advanced lung adenocarcinoma
Sholf, L. M.
Janne, P. A.
Jackman, D. M.
Joshi, V. A.
Lindeman, N. I.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2007, 9 (05): : 692 - 692
[25] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China
Jianlin Xu
Yanwei Zhang
Bo Jin
Tianqing Chu
Xue Dong
Haitang Yang
Dan Wu
Yuqing Lou
Xueyan Zhang
Huiming Wang
Baohui Han
Journal of Cancer Research and Clinical Oncology, 2016, 142 : 1325 - 1330
[26] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China
Xu, Jianlin
Zhang, Yanwei
Jin, Bo
Chu, Tianqing
Dong, Xue
Yang, Haitang
Wu, Dan
Lou, Yuqing
Zhang, Xueyan
Wang, Huiming
Han, Baohui
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (06) : 1325 - 1330
[27] EGFR Mutations in Asian Patients with Advanced Lung Adenocarcinoma
Liam, Chong-Kin
Pang, Yong-Kek
Poh, Mau-Ern
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : E70 - E71
[28] Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Blanco Cid, Nagore
Parente Lamelas, Isaura
Abal Arca, Jose
Gomez Marquez, Hugo
Marcos Velazquez, Pedro
EUROPEAN RESPIRATORY JOURNAL, 2013, 42
[29] Extraordinary Response to Erlotinib Therapy in a Patient with Lung Adenocarcinoma Exhibiting KRAS Mutation and EGFR Amplification
Krejci, J.
Pesek, M.
Grossmann, P.
Krejci, M.
Ricar, J.
Benesova, L.
Minarik, M.
CANCER GENOMICS & PROTEOMICS, 2011, 8 (03) : 135 - 138
[30] MONITORING OF EGFR TKI SENSITIZING AND RESISTANCE MUTATIONS IN PLASMA DNA OF ADVANCED ADENOCARCINOMA OF NSCLC DURING ERLOTINIB TREATMENT.
Sorensen, Boe
Wu, Lin
Wen, Wei
Tsai, Julie
Weber, Britta
Nexo, Ebba
Meldgaard, Peter
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S386 - S387

← 1 2 3 4 5 →